BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 31056729)

  • 1. Malignant Melanoma: Autoimmunity and Supracellular Messaging as New Therapeutic Approaches.
    Motofei IG
    Curr Treat Options Oncol; 2019 May; 20(6):45. PubMed ID: 31056729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melanoma and autoimmunity: spontaneous regressions as a possible model for new therapeutic approaches.
    Motofei IG
    Melanoma Res; 2019 Jun; 29(3):231-236. PubMed ID: 30615013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
    Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biology of Cancer; From Cellular Cancerogenesis to Supracellular Evolution of Malignant Phenotype.
    Motofei IG
    Cancer Invest; 2018; 36(5):309-317. PubMed ID: 30010428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequencing of New and Old Therapies for Metastatic Melanoma.
    Ratterman M; Hallmeyer S; Richards J
    Curr Treat Options Oncol; 2016 Oct; 17(10):52. PubMed ID: 27515170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploiting autoimmunity unleashed by low-dose immune checkpoint blockade to treat advanced cancer.
    Bakacs T; Moss RW; Kleef R; Szasz MA; Anderson CC
    Scand J Immunol; 2019 Dec; 90(6):e12821. PubMed ID: 31589347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination Immunotherapy Development in Melanoma.
    Eggermont AMM; Crittenden M; Wargo J
    Am Soc Clin Oncol Educ Book; 2018 May; 38():197-207. PubMed ID: 30231333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.
    Kakavand H; Wilmott JS; Long GV; Scolyer RA
    Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.
    Ascierto PA; Capone M; Grimaldi AM; Mallardo D; Simeone E; Madonna G; Roder H; Meyer K; Asmellash S; Oliveira C; Roder J; Grigorieva J
    J Immunother Cancer; 2019 Mar; 7(1):91. PubMed ID: 30925943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
    Kelley MC
    Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.
    Hermel DJ; Ott PA
    Cancer Metastasis Rev; 2017 Mar; 36(1):43-50. PubMed ID: 28181070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Advances and Treatment Options in Metastatic Melanoma.
    Johnson DB; Sosman JA
    JAMA Oncol; 2015 Jun; 1(3):380-6. PubMed ID: 26181188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma.
    Margolin K
    Curr Treat Options Oncol; 2016 Sep; 17(9):48. PubMed ID: 27461037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers in melanoma.
    Griewank KG
    Scand J Clin Lab Invest Suppl; 2016; 245():S104-12. PubMed ID: 27467728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of immune related adverse events induced by immune checkpoint inhibition.
    Teufel A; Zhan T; Härtel N; Bornschein J; Ebert MP; Schulte N
    Cancer Lett; 2019 Aug; 456():80-87. PubMed ID: 31051213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review.
    Ouwerkerk W; van den Berg M; van der Niet S; Limpens J; Luiten RM
    Melanoma Res; 2019 Oct; 29(5):453-464. PubMed ID: 30855527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and Management of Acral Lentiginous Melanoma.
    Nakamura Y; Fujisawa Y
    Curr Treat Options Oncol; 2018 Jun; 19(8):42. PubMed ID: 29951919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.